Your browser doesn't support javascript.
loading
Ovarian stimulation for IVF and risk of primary breast cancer in BRCA1/2 mutation carriers.
Derks-Smeets, Inge A P; Schrijver, Lieske H; de Die-Smulders, Christine E M; Tjan-Heijnen, Vivianne C G; van Golde, Ron J T; Smits, Luc J; Caanen, Beppy; van Asperen, Christi J; Ausems, Margreet; Collée, Margriet; van Engelen, Klaartje; Kets, C Marleen; van der Kolk, Lizet; Oosterwijk, Jan C; van Os, Theo A M; Rookus, Matti A; van Leeuwen, Flora E; Gómez García, Encarna B.
Afiliação
  • Derks-Smeets IAP; Department of Clinical Genetics, Maastricht University Medical Centre+, P.O. Box 5800, 6202 AZ, Maastricht, The Netherlands.
  • Schrijver LH; GROW - School for Oncology and Developmental Biology, Maastricht University, P.O. Box 616, 6200 MD, Maastricht, The Netherlands.
  • de Die-Smulders CEM; Department of Epidemiology, Netherlands Cancer Institute, Plesmanlaan 121, 1066 CX, Amsterdam, Netherlands.
  • Tjan-Heijnen VCG; Department of Clinical Genetics, Maastricht University Medical Centre+, P.O. Box 5800, 6202 AZ, Maastricht, The Netherlands.
  • van Golde RJT; GROW - School for Oncology and Developmental Biology, Maastricht University, P.O. Box 616, 6200 MD, Maastricht, The Netherlands.
  • Smits LJ; GROW - School for Oncology and Developmental Biology, Maastricht University, P.O. Box 616, 6200 MD, Maastricht, The Netherlands.
  • Caanen B; Department of Internal Medicine, Division of Medical Oncology, Maastricht University Medical Centre+, P.O. Box 5800, 6202 AZ, Maastricht, The Netherlands.
  • van Asperen CJ; GROW - School for Oncology and Developmental Biology, Maastricht University, P.O. Box 616, 6200 MD, Maastricht, The Netherlands.
  • Ausems M; Department of Obstetrics and Gynaecology, Maastricht University Medical Centre+, P.O. Box 5800, 6202 AZ, Maastricht, The Netherlands.
  • Collée M; Department of Epidemiology, Maastricht University, P.O. Box 616, 6200 MD, Maastricht, The Netherlands.
  • van Engelen K; Department of Clinical Genetics, Maastricht University Medical Centre+, P.O. Box 5800, 6202 AZ, Maastricht, The Netherlands.
  • Kets CM; Department of Clinical Genetics, Leiden University Medical Centre Leiden, P.O. Box 9600, 2300 RC, Leiden, The Netherlands.
  • van der Kolk L; Department of Genetics, University Medical Centre Utrecht, P.O. 85500, 3508 GA, Utrecht, The Netherlands.
  • Oosterwijk JC; Department of Clinical Genetics, Erasmus University Medical Center, P.O. Box 2040, 3000 CA, Rotterdam, The Netherlands.
  • van Os TAM; Department of Clinical Genetics, VU University Medical Centre, P.O. Box 7057, 1007 MB, Amsterdam, The Netherlands.
  • Rookus MA; Family Cancer Clinic, Netherlands Cancer Institute, Plesmanlaan 121, 1066 CX, Amsterdam, The Netherlands.
  • van Leeuwen FE; Department of Genetics, University of Groningen, University Medical Center Groningen, P.O. Box 30.001, 9700 RB, Groningen, The Netherlands.
  • Gómez García EB; Department of Clinical Genetics, Academic Medical Centre, P.O. Box 22700, 1100 DE, Amsterdam, The Netherlands.
Br J Cancer ; 119: 357-363, 2018 05 01.
Artigo em Inglês | MEDLINE | ID: mdl-29937543
ABSTRACT

BACKGROUND:

The effect of in vitro fertilisation (IVF) on breast cancer risk for BRCA1/2 mutation carriers is rarely examined. As carriers may increasingly undergo IVF as part of preimplantation genetic diagnosis (PGD), we examined the impact of ovarian stimulation for IVF on breast cancer risk in BRCA1/2 mutation carriers.

METHODS:

The study population consisted of 1550 BRCA1 and 964 BRCA2 mutation carriers, derived from the nationwide HEBON study and the nationwide PGD registry. Questionnaires, clinical records and linkages with the Netherlands Cancer Registry were used to collect data on IVF exposure, risk-reducing surgeries and cancer diagnosis, respectively. Time-dependent Cox regression analyses were conducted, stratified for birth cohort and adjusted for subfertility.

RESULTS:

Of the 2514 BRCA1/2 mutation carriers, 3% (n = 76) were exposed to ovarian stimulation for IVF. In total, 938 BRCA1/2 mutation carriers (37.3%) were diagnosed with breast cancer. IVF exposure was not associated with risk of breast cancer (HR 0.79, 95% CI 0.46-1.36). Similar results were found for the subgroups of subfertile women (n = 232; HR 0.73, 95% CI 0.39-1.37) and BRCA1 mutation carriers (HR 1.12, 95% CI 0.60-2.09). In addition, age at and recency of first IVF treatment were not associated with breast cancer risk.

CONCLUSION:

No evidence was found for an association between ovarian stimulation for IVF and breast cancer risk in BRCA1/2 mutation carriers.
Assuntos
Texto completo: Disponível Coleções: Bases de dados internacionais Base de dados: MEDLINE Assunto principal: Indução da Ovulação / Neoplasias da Mama / Fertilização In Vitro / Genes BRCA1 / Genes BRCA2 / Heterozigoto / Mutação Limite: Adulto / Idoso / Feminino / Humanos / Meia-Idade Idioma: Inglês Revista: Br J Cancer Ano de publicação: 2018 Tipo de documento: Artigo País de afiliação: Holanda

Similares

MEDLINE

...
LILACS

LIS

Texto completo: Disponível Coleções: Bases de dados internacionais Base de dados: MEDLINE Assunto principal: Indução da Ovulação / Neoplasias da Mama / Fertilização In Vitro / Genes BRCA1 / Genes BRCA2 / Heterozigoto / Mutação Limite: Adulto / Idoso / Feminino / Humanos / Meia-Idade Idioma: Inglês Revista: Br J Cancer Ano de publicação: 2018 Tipo de documento: Artigo País de afiliação: Holanda